Cardiovascular Diseases

Subclinical AF Common in HF Patients

A cohort study revealed that subclinical atrial fibrillation (AF) was common in heart failure (HF) patients with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF). The study included 367 patients with cardiac monitoring data at baseline and follow-up in a randomized clinical trial of atrial shunt therapy. The median patch monitoring time was 6 and 125 days at baseline and over a 12-month follow-up, respectively. 194 (53%) patients had a history of AF or atrial flutter (AFL), and median baseline AF burden was 0.012%. After multivariable adjustment, baseline AF burden ≥0.012% was significantly associated with HF events (HR: 2.00) regardless of a history of AF or AFL. Adjustment for left atrial reservoir strain attenuated the baseline AF burden-HF event association (HR: 1.71). 141 (38%) patients had patch-detected AF during follow-up without a history of AF or AFL. Atrial shunt therapy did not reduce the total rate of HF events or improve health status, it did not change AF incidence or burden during follow-up either. The findings indicate that subclinical AF is common in patients with HFpEF and HFmrEF and baseline AF burden is associated with HF events. Source: https://www.jacc.org/; https://www.thelancet.com/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

20 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

22 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.